We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
- Authors
Parisi, Sarah; Ruggeri, Loredana; Dan, Elisa; Rizzi, Simonetta; Sinigaglia, Barbara; Ocadlikova, Darina; Bontadini, Andrea; Giudice, Valeria; Urbani, Elena; Ciardelli, Sara; Sartor, Chiara; Cristiano, Gianluca; Nanni, Jacopo; Zannoni, Letizia; Chirumbolo, Gabriella; Arpinati, Mario; Lewis, Russell E.; Bonifazi, Francesca; Marconi, Giovanni; Martinelli, Giovanni
- Abstract
Recently, many reports were published supporting the clinical use of adoptively transferred natural killer (NK) cells as a therapeutic tool against cancer, including acute myeloid leukemia (AML). Our group demonstrated promising clinical response using adoptive immunotherapy with donor-derived alloreactive KIR-ligand-mismatched NK cells in AML patients. Moreover, the antileukemic effect was correlated with the dose of infused alloreactive NK cells ("functional NK cell dose"). Herein, we update the results of our previous study on a cohort of adult AML patients (median age at enrollment 64) in first morphological complete remission (CR), not eligible for allogeneic stem cell transplantation. After an extended median follow-up of 55.5 months, 8/16 evaluable patients (50%) are still off-therapy and alive disease-free. Overall survival (OS) and disease-free survival (DFS) are related with the dose of infused alloreactive NK cells (≥2 × 105/kg).
- Subjects
KILLER cells; ACUTE myeloid leukemia; STEM cell transplantation; CANCER remission; IMMUNOTHERAPY
- Publication
Frontiers in Immunology, 2022, Vol 13, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2021.804988